PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyGlobeNewsWire • 09/28/22
PepGen Reports Second Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 08/12/22
PepGen Appoints Caroline Godfrey, Ph.D. to the Company's Scientific Advisory BoardGlobeNewsWire • 07/22/22
PepGen Reports First Quarter 2022 Financial Results and Recent Corporate DevelopmentsGlobeNewsWire • 06/16/22